Perino AC, Fan J, Schmitt S, et al. - The use of direct oral anticoagulants (DOACs) in venous thromboembolism (VTE) is prohibited for patients ≥ 120 kg and ≥ 40 kg/m² as per consensus statements. In this study, the use and outcomes of DOACs for VTE were investigated across weight and BMI.

• A total of 51,871 patients prescribed DOAC or warfarin within 30 days of index VTE diagnosis (age 64.5±13.1 years; 6.0% female; median weight 93.4 kg [25th–75th: 80.5–108.6 kg]) were included in the analysis cohort.

• Treatment with DOAC was recorded in 38.4% of patients with weight ≥ 120 kg (N = 6,934 patients) vs 45.4% of those weighing ≥ 60 to < 100 kg (N = 30,645).

• Overall DOAC is frequently prescribed for patients ≥ 120 kg and ≥ 40 kg/m² with VTE, without an elevated risk of bleeding or recurrent VTE.

• Findings suggest that this population can be safely and effectively managed using DOACs.